Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial.

To date, 40 participants have been dosed with SGT-003 and it has generally been well tolerated. Click here to read Solid’s letter to the community with further details.